TikoMed AB reports positive phase II clinical data for the treatment of Amyothropic Lateral Sclerosis in data published by PLOS ONE

Viken – 25th May, 2022 – A new study with TikoMed’s platform lead clinical drug candidate ILB®\,\[ ]provides positive safety and tolerability results and the first clinical evidence of encouraging clinical efficacy of ILB® in the treatment of amyotrophic lateral sclerosis (ALS). The study was published in PLOS ONE today. In a Phase II study of ILB® administered to patients with ALS for five weeks, the progression of ALS was halted and/or reversed for all study participants assessed using the validated ALSFRS-R and Norris clincal rating scales that score a broad range of patient relevant